search
Back to results

Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections [cSSSI] (ASSIST-2)

Primary Purpose

Skin Diseases, Bacterial

Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
Intravenous iclaprim
Intravenous linezolid
Sponsored by
Arpida AG
About
Eligibility
Locations
Outcomes
Full info

About this trial

This is an interventional treatment trial for Skin Diseases, Bacterial focused on measuring skin infection, complicated skin infection, skin structure infection, Complicated Skin and Skin Structure Infection

Eligibility Criteria

18 Years - 90 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Diagnosis of an infection consistent with complicated skin and skin structure infection due to a gram positive pathogen. Exclusion Criteria: Known or suspected hypersensitivity to any study medication or other related anti-infective medication Any known or suspected condition or concurrent treatment contraindicated by the prescribing information Previous enrollment in this study Treatment with any investigational drug within 30 days before enrollment

Sites / Locations

  • Edward Hospital & Health Services
  • Wyoming Medical Center

Outcomes

Primary Outcome Measures

Clinical cure rate (the ratio of number of clinically cured patients to the total number of patients in the population) at 7 to 14 days after the end of therapy

Secondary Outcome Measures

Microbiological eradication rate at 7-14 days after end of therapy
Safety evaluations conducted during the study

Full Information

First Posted
March 15, 2006
Last Updated
March 26, 2007
Sponsor
Arpida AG
search

1. Study Identification

Unique Protocol Identification Number
NCT00303550
Brief Title
Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections [cSSSI] (ASSIST-2)
Official Title
Phase 3, Randomized, Investigator-Blind, Multi-Center Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections (ASSIST-2)
Study Type
Interventional

2. Study Status

Record Verification Date
March 2006
Overall Recruitment Status
Completed
Study Start Date
March 2006 (undefined)
Primary Completion Date
undefined (undefined)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Name of the Sponsor
Arpida AG

4. Oversight

5. Study Description

Brief Summary
The study is now completed
Detailed Description
Primary Objective: The primary objective of this study is to compare the clinical cure rates of iclaprim and linezolid at the test of cure (TOC) visit (7 to 14 days after the end of treatment). Secondary Objectives: The secondary objectives of this study are to compare iclaprim with linezolid regarding: Clinical efficacy at the end of study medication treatment; Time to resolution of systemic and local signs and symptoms of complicated skin and skin structure infection (cSSSI); Clinical outcome in the microbiologically evaluable (ME) population; Bacteriologic outcome in the ME population; Bacteriologic eradication rates of Baseline (BL) pathogens; Clinical outcome in the modified intent-to-treat (MITT) population; Bacteriologic outcome in the MITT population; Baseline in vitro susceptibility of isolated pathogens in the ME population; and Safety and tolerability of iclaprim treatment.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Skin Diseases, Bacterial
Keywords
skin infection, complicated skin infection, skin structure infection, Complicated Skin and Skin Structure Infection

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized

8. Arms, Groups, and Interventions

Intervention Type
Drug
Intervention Name(s)
Intravenous iclaprim
Intervention Type
Drug
Intervention Name(s)
Intravenous linezolid
Primary Outcome Measure Information:
Title
Clinical cure rate (the ratio of number of clinically cured patients to the total number of patients in the population) at 7 to 14 days after the end of therapy
Secondary Outcome Measure Information:
Title
Microbiological eradication rate at 7-14 days after end of therapy
Title
Safety evaluations conducted during the study

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
90 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Diagnosis of an infection consistent with complicated skin and skin structure infection due to a gram positive pathogen. Exclusion Criteria: Known or suspected hypersensitivity to any study medication or other related anti-infective medication Any known or suspected condition or concurrent treatment contraindicated by the prescribing information Previous enrollment in this study Treatment with any investigational drug within 30 days before enrollment
Facility Information:
Facility Name
Edward Hospital & Health Services
City
Naperville
State/Province
Illinois
ZIP/Postal Code
60540
Country
United States
Facility Name
Wyoming Medical Center
City
Casper
State/Province
Wyoming
ZIP/Postal Code
82601
Country
United States

12. IPD Sharing Statement

Links:
URL
http://www.arpida.ch
Description
ARPIDA AG corporate website

Learn more about this trial

Study of Intravenous (I.V.) Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections [cSSSI] (ASSIST-2)

We'll reach out to this number within 24 hrs